PAMINE FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PAMINE FORTE (PAMINE FORTE).
Anticholinergic agent; competitively blocks acetylcholine at muscarinic receptors, reducing gastrointestinal motility and secretory activity.
| Metabolism | Hepatic metabolism (CYP450 enzymes, primarily CYP2D6 and CYP3A4). |
| Excretion | Renal (70% unchanged), biliary/fecal (30%) |
| Half-life | 1.5-2 hours; prolonged in renal impairment |
| Protein binding | 40% bound to albumin |
| Volume of Distribution | 4.2 L/kg; indicates extensive tissue distribution |
| Bioavailability | Oral: 10-25% due to first-pass metabolism; IM: 100% |
| Onset of Action | Oral: 1 hour; IM: 15-30 minutes; IV: 1-2 minutes |
| Duration of Action | 3-4 hours for anticholinergic effects; gastric acid suppression up to 6 hours |
| Molecular Weight | 345.6 |
1 tablet (5 mg) orally 4 times daily, before meals and at bedtime.
| Dosage form | TABLET |
| Renal impairment | No specific GFR-based adjustments are established; use with caution in severe renal impairment (CrCl <30 mL/min) due to potential for increased adverse effects. |
| Liver impairment | No specific Child-Pugh based modifications are established; use with caution in severe hepatic impairment. |
| Pediatric use | Safety and efficacy not established; use not recommended. |
| Geriatric use | Elderly patients may be more sensitive to anticholinergic effects; initiate at lowest effective dose, titrate carefully. |
| 1st trimester | No well-controlled studies; use only if clearly needed and benefit outweighs risk. |
| 2nd trimester | No well-controlled studies; use only if clearly needed and benefit outweighs risk. |
| 3rd trimester | Consider anticholinergic effects on neonate (e.g., ileus, respiratory depression). Avoid use near term. |
Clinical note
Comprehensive clinical and safety monograph for PAMINE FORTE (PAMINE FORTE).
| Placental transfer | Crosses placenta; degree not quantified. |
| Breastfeeding | Limited data; anticholinergic drugs may suppress lactation and cause infant anticholinergic effects (e.g., tachycardia, irritability). Use with caution. |
| Lactation Rating |
■ FDA Black Box Warning
None.
| Serious Effects |
GlaucomaObstructive uropathyObstructive gastrointestinal diseaseMyasthenia gravisSevere ulcerative colitisToxic megacolonHypersensitivity to the drug
| Precautions | May cause drowsiness, blurred vision, heat prostration, urinary retention, and constipation. Use with caution in patients with glaucoma, myasthenia gravis, autonomic neuropathy, and renal/hepatic impairment. |
| Food/Dietary | Avoid high-fat meals which may reduce drug absorption. Concurrent use of alcohol may increase CNS depression. Avoid excessive caffeine intake as it may counteract therapeutic effects. |
| Clinical Pearls |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | PAMINE FORTE (methscopolamine bromide) is an anticholinergic agent. Data on fetal risks in humans are limited. Animal studies have not reported teratogenic effects. First trimester: No well-controlled studies; risk cannot be excluded. Second and third trimesters: Use only if clearly needed; anticholinergics may cause fetal tachycardia, decreased GI motility, and potential respiratory depression in neonates if used near term. |
| Fetal Monitoring | Monitor maternal heart rate and blood pressure; assess for signs of anticholinergic toxicity (e.g., blurred vision, urinary retention). Fetal monitoring: heart rate surveillance if used near term; evaluate for neonatal anticholinergic effects post-delivery. |
| Fertility Effects | No specific data on fertility impairment in humans. Anticholinergics may theoretically affect reproductive function by altering cholinergic signaling; clinical significance unknown. |
| PAMINE FORTE (methscopolamine bromide) is a quaternary ammonium anticholinergic that does not cross the blood-brain barrier significantly, reducing CNS side effects. Monitor for anticholinergic toxicity, especially in elderly, patients with renal impairment, or those on other anticholinergics. Contraindicated in glaucoma, obstructive uropathy, and myasthenia gravis. Use with caution in patients with hyperthyroidism, coronary artery disease, or hiatal hernia. |
| Patient Advice | Take exactly as prescribed. Do not crush or chew extended-release tablets. · Avoid alcohol and other CNS depressants as they may increase drowsiness. · Report signs of anticholinergic toxicity: dry mouth, blurred vision, constipation, difficulty urinating, confusion. · Avoid overheating and dehydration; may decrease sweating and increase risk of heat stroke. · Use caution when driving or operating machinery until effects are known. · Do not take with antacids or medications for diarrhea; separate by at least 2 hours. |